Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | FER | P16591 | 2/20 | 0.43 |
| ▸ | LTK | P29376 | 2/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 5/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.38 |
| ▸ | GSK3A | P49840 | 4/20 | 0.38 |
| ▸ | PLK4 | O00444 | 4/20 | 0.38 |
| ▸ | AURKA | O14965 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203198 | 0.79 | LRRK2 (0.50) | MAPTLMNAGAAACVR1LRRK2 | |
| SCHEMBL7980321 | 0.79 | MAPT (0.56) | MAPTLMNAGAAACVR1LRRK2 | |
| SCHEMBL20505096 | 0.77 | MAPT (0.44) | MAPTLMNAGAAACVR1LRRK2 | |
| SCHEMBL20723 | 0.77 | MAPT (0.44) | MAPTLMNAGAAACVR1LRRK2 | |
| SCHEMBL8121209 | 0.76 | GRIN2D (0.35) | MAPTLMNAGAAACVR1LRRK2 | |
| SCHEMBL240371 | 0.76 | MAPT (0.43) | MAPTLMNAGAAACVR1LRRK2 | |
| SCHEMBL8556891 | 0.72 | RET (0.37) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL8555812 | 0.72 | TGM2 (0.50) | MAPTLMNALRRK2FERCYP1A2 | |
| SCHEMBL5760370 | 0.72 | ROS1 (0.46) | MAPTLMNAGAAACVR1LRRK2 | |
| SCHEMBL8555842 | 0.72 | KMT2A (0.39) | MAPTLRRK2MAOAMAOBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318355-B1 | 1,1'-DIADAMANTYL CARBOXYLIC ACIDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2018-09-12 | — | — | EP | claimed |
| EP-2496559-B1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE AND THEIR USE AS HSD 1 INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2018-01-10 | — | — | EP | claimed |
| EP-2350068-B1 | UREA DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2017-08-30 | — | — | EP | claimed |
| US-9663470-B2 | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | claimed |
| EP-2288596-B1 | ALICYCLIC CARBOXYLIC ACID DERIVATIVES OF BENZOMORPHANS AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE | BOEHRINGER INGELHEIM INT (DE) | 2016-11-30 | — | — | EP | claimed |
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-22 | — | — | US | claimed |
| US-9328072-B2 | Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | claimed |
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | claimed |
| CN-105037326-A | Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline | VITAE PHARMACEUTICALS INC | 2015-11-11 | — | — | CN | claimed |
| US-9073870-B2 | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-07 | — | — | US | claimed |
| EP-0732942-A4 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | COCENSYS INC (US) | 2000-03-22 | — | — | EP | claimed |
| US-5955464-A | USE OF THE RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES OF THE COMPOUNDS IN THE TREATMENT OF PROLIFERATIVE DISEASE SUCH AS CANCER | ZENECA LIMITED (GB) | 1999-09-21 | — | — | US | claimed |
| EP-0794953-B1 | QUINAZOLINE DERIVATIVES | ZENECA LTD (GB) | 1999-05-06 | — | — | EP | claimed |
| EP-0647137-A4 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF. | UNIV CALIFORNIA WEBER ECKARD (US) | 1998-09-16 | — | — | EP | claimed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | claimed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | claimed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | claimed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | claimed |
| US-4042577-A | POLYESTERS, POLYAMIDES, CELLULOSE ACETATES | SANDOZ LTD. (CH) | 1977-08-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272590-A1 | ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE | HSD17B1, HSD3B1, HSD11B1 | MAPT 4729/4885LMNA 3209/4885GAA 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.